276 related articles for article (PubMed ID: 33183946)
1. Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study.
Patel RS; Sreeram V; Vadukapuram R; Baweja R
Schizophr Res; 2020 Oct; 224():40-44. PubMed ID: 33183946
[TBL] [Abstract][Full Text] [Related]
2. Cannabis use and medication nonadherence in bipolar disorder: A nationwide inpatient sample database analysis.
Oladunjoye AF; Kaleem SZ; Suresh A; Sahni V; Thoonkuzhy MJ; Anugwom G; Oladunjoye O; Otuada D; Ikekwere J; Espiridion ED
J Affect Disord; 2022 Feb; 299():174-179. PubMed ID: 34863715
[TBL] [Abstract][Full Text] [Related]
3. Region-Wise Distribution of Schizophrenia With Cannabis Abuse and Medication Non-Compliance in the United States: A Nationwide Analysis of 51,975 Hospitalizations.
Vadukapuram R; Zahid S; Lee HK; Patel RS
Cureus; 2020 May; 12(5):e7936. PubMed ID: 32494541
[TBL] [Abstract][Full Text] [Related]
4. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
[TBL] [Abstract][Full Text] [Related]
5. Comorbid Cannabis and Tobacco Use Disorders in Hospitalized Patients with Psychotic-Spectrum Disorders.
Reeves LE; Gaudiano BA; Metrik J; Guzman Holst C; Morena A; Sydnor VJ; Weinstock LM; Epstein-Lubow G
J Dual Diagn; 2018; 14(3):171-180. PubMed ID: 30265850
[TBL] [Abstract][Full Text] [Related]
6. Relationship of Cannabis Use Disorder and Irritable Bowel Syndrome (IBS): An Analysis of 6.8 Million Hospitalizations in the United States.
Patel RS; Goyal H; Satodiya R; Tankersley WE
Subst Use Misuse; 2020; 55(2):281-290. PubMed ID: 31573379
[No Abstract] [Full Text] [Related]
7. The prevalence of Healthcare Effectiveness Data and Information Set (HEDIS) initiation and engagement in treatment among patients with cannabis use disorders in 7 US health systems.
Lapham GT; Campbell CI; Yarborough BJH; Hechter RC; Ahmedani BK; Haller IV; Kline-Simon AH; Satre DD; Loree AM; Weisner C; Binswanger IA
Subst Abus; 2019; 40(3):268-277. PubMed ID: 30657438
[No Abstract] [Full Text] [Related]
8. [Cannabis and schizophrenia: demographic and clinical correlates].
Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
[TBL] [Abstract][Full Text] [Related]
9. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders.
Koenders L; Machielsen MW; van der Meer FJ; van Gasselt AC; Meijer CJ; van den Brink W; Koeter MW; Caan MW; Cousijn J; den Braber A; van 't Ent D; Rive MM; Schene AH; van de Giessen E; Huyser C; de Kwaasteniet BP; Veltman DJ; de Haan L
J Psychiatry Neurosci; 2015 May; 40(3):197-206. PubMed ID: 25510948
[TBL] [Abstract][Full Text] [Related]
10. Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients.
Katz G; Kunyvsky Y; Hornik-Lurie T; Raskin S; Abramowitz MZ
Isr J Psychiatry Relat Sci; 2016; 53(3):10-15. PubMed ID: 28492376
[TBL] [Abstract][Full Text] [Related]
11. Cannabis use and cannabis use disorders among individuals with mental illness.
Lev-Ran S; Le Foll B; McKenzie K; George TP; Rehm J
Compr Psychiatry; 2013 Aug; 54(6):589-98. PubMed ID: 23375264
[TBL] [Abstract][Full Text] [Related]
12. Cannabis use disorder and increased risk of arrhythmia-related hospitalization in young adults.
Patel RS; Gonzalez MD; Ajibawo T; Baweja R
Am J Addict; 2021 Nov; 30(6):578-584. PubMed ID: 34432919
[TBL] [Abstract][Full Text] [Related]
13. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis.
Koskinen J; Löhönen J; Koponen H; Isohanni M; Miettunen J
Schizophr Bull; 2010 Nov; 36(6):1115-30. PubMed ID: 19386576
[TBL] [Abstract][Full Text] [Related]
14. Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review.
Lees R; Hines LA; D'Souza DC; Stothart G; Di Forti M; Hoch E; Freeman TP
Psychol Med; 2021 Feb; 51(3):353-364. PubMed ID: 33536109
[TBL] [Abstract][Full Text] [Related]
15. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.
Hambrecht M; Häfner H
Aust N Z J Psychiatry; 2000 Jun; 34(3):468-75. PubMed ID: 10881971
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia.
Miller R; Ream G; McCormack J; Gunduz-Bruce H; Sevy S; Robinson D
Schizophr Res; 2009 Sep; 113(2-3):138-44. PubMed ID: 19481424
[TBL] [Abstract][Full Text] [Related]
17. The association between cannabis use and anxiety disorders: Results from a population-based representative sample.
Feingold D; Weiser M; Rehm J; Lev-Ran S
Eur Neuropsychopharmacol; 2016 Mar; 26(3):493-505. PubMed ID: 26775742
[TBL] [Abstract][Full Text] [Related]
18. The association between lifetime cannabis use and dysthymia across six birth decades.
Livne O; Razon L; Rehm J; Hasin DS; Lev-Ran S
J Affect Disord; 2018 Jul; 234():327-334. PubMed ID: 29605793
[TBL] [Abstract][Full Text] [Related]
19. Cannabis use disorder, suicide attempts, and self-harm among adolescents: A national inpatient study across the United States.
Oladunjoye AF; Li E; Aneni K; Onigu-Otite E
PLoS One; 2023; 18(10):e0292922. PubMed ID: 37847698
[TBL] [Abstract][Full Text] [Related]
20. Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder.
Weinstock LM; Gaudiano BA; Wenze SJ; Epstein-Lubow G; Miller IW
Compr Psychiatry; 2016 Feb; 65():57-62. PubMed ID: 26773991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
